Optic Neuritis
Conditions
Brief summary
Mean change from baseline in LCVA at Month 3 in the study eye.
Detailed description
•First (Key) Secondary: Proportion of participants achieving at least a 6-line (30-letter) gain from baseline in LCVA at Month 3 in the study eye., • Mean change from baseline in the GCIPL thickness as measured by optical coherence tomography (OCT) at Month 3 in the study eye., • Serum neurofilament light chain (sNfL) mean change from baseline through Month 3., •Mean change from baseline in NEI VFQ 25 at Month 3., •Mean change from baseline in NOS-10 at Month 3.
Interventions
DRUGPrivosegtor
DRUG0.9% sodium chloride sterile saline solution (sodium chloride [NaCl]) for IV infusion
DRUGmatching the solution used in preparing the active treatment.
Sponsors
Oculis Operations SARL
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean change from baseline in LCVA at Month 3 in the study eye. | — |
Secondary
| Measure | Time frame |
|---|---|
| •First (Key) Secondary: Proportion of participants achieving at least a 6-line (30-letter) gain from baseline in LCVA at Month 3 in the study eye., • Mean change from baseline in the GCIPL thickness as measured by optical coherence tomography (OCT) at Month 3 in the study eye., • Serum neurofilament light chain (sNfL) mean change from baseline through Month 3., •Mean change from baseline in NEI VFQ 25 at Month 3., •Mean change from baseline in NOS-10 at Month 3. | — |
Outcome results
None listed